Sun Pharma, a company headquartered in Mumbai, India, is to acquire biomedical company Checkpoint Therapeutics for approximately $355 million. Checkpoint Therapeutics is a commercial-stage immunotherapy and targeted oncology company focused on the development and commercialisation of novel treatments for patients with solid tumour cancers; this acquisition will include Unloxcyt (cosibelimab-ipdl), Checkpoint’s FDA-approved anti-PD-L1 therapy for metastatic and locally advanced cutaneous squamous cell carcinoma (cSCC).

The deal is expected to be completed by the end the second half of 2025 and is subject to customary closing conditions. Upon completion of the transaction, Sun Pharma will acquire all outstanding shares of Checkpoint.